CAR T Excels in Second-Line Lymphoma Care
Lisocabtagene maraleucel demonstrated superior efficacy with median event-free survival of 29.5 months compared to 2.4 months for standard of care in second-line large B-cell lymphoma (LBCL). The 36-month overall survival rate reached 63% for lisocabtagene maraleucel vs 52% for standard care, with progression-free survival rates of 51% vs 26.5%, respectively.
METHODOLOGY:
A total of 184 adults eligible for autologous stem cell transplantation were randomly assigned 1:1 to receive either lisocabtagene maraleucel or standard of care.
Participants in the lisocabtagene maraleucel arm received a target dose of 100 × 10 6 chimeric antigen receptor-positive (CAR) T cells, while the standard-of-care arm received three cycles of protocol-defined immunochemotherapy, followed by high-dose chemotherapy and autologous stem cell transplantation.
chimeric antigen receptor-positive (CAR) T cells, while the standard-of-care arm received three cycles of protocol-defined immunochemotherapy, followed by high-dose chemotherapy and autologous stem cell transplantation. Bridging therapy was permitted at investigator discretion for disease control during lisocabtagene maraleucel manufacturing.
The study was conducted following Declaration of Helsinki guidelines, International Conference on Harmonisation Good Clinical Practice guidelines, and applicable regulatory requirements.
TAKEAWAY:
Median event-free survival was 29.5 months for lisocabtagene maraleucel vs 2.4 months for standard of care (hazard ratio [HR], 0.375; 95% CI, 0.259-0.542).
Median progression-free survival was not reached for lisocabtagene maraleucel vs 6.2 months for standard of care, with 36-month rates of 51% vs 26.5%.
The 36-month overall survival rate was 63% for lisocabtagene maraleucel vs 52% for standard of care.
At 3-year follow-up, lisocabtagene maraleucel demonstrated superior, more durable efficacy vs standard of care with a favorable safety profile and no new safety signals.
IN PRACTICE:
'These results provide long-term evidence to support liso-cel [lisocabtagene maraleucel] as an effective second-line treatment with curative potential for patients with primary refractory/early relapsed LBCL,' the authors of the study wrote.
SOURCE:
The study was led by Manali Kamdar, MD, MBBS, University of Colorado Cancer Center in Aurora, Colorado. It was published online in Journal of Clinical Oncology.
LIMITATIONS:
When interpreting overall survival data, the crossover design of the study needs to be considered. Additionally, the study was not powered to evaluate statistical differences in overall survival between treatment arms due to limited number of events in both groups.
DISCLOSURES:
The study was supported by Celgene, a Bristol Myers Squibb Company. Additional disclosures are noted in the original article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Acorn Health Names Mony Iyer CEO
CORAL GABLES, Fla., August 21, 2025--(BUSINESS WIRE)--Acorn Health, a leading national provider of applied behavior analysis (ABA) therapy for children diagnosed with autism spectrum disorder (ASD), announces Mony Iyer as its new president and chief executive officer, effective Sept. 15, 2025. "We are delighted to welcome Mony to Acorn Health," said Imran Siddiqui, a member of Acorn Health's board of directors and managing director of Ontario Teachers' Pension Plan. "A nationally recognized business leader, he brings the unique combination of championing culture and inspiring teams while scaling organizations with purpose. We are excited to support him as he leads Acorn Health into its next stage of growth and impact." Iyer has more than 20 years of experience leading large, mission-driven organizations. Most recently, he served as president of Banfield Pet Hospital, one of the largest veterinary companies in the US. Prior to that he was vice president of specialty healthcare services for Walmart, president of OneSight and vice president for Luxottica Group. "What drew me to Acorn Health is its clear mission and strong culture of care," said Iyer. "Over the course of my career, I have experienced how empowering teams and clinicians leads to better outcomes for those we serve. I am eager to build on that foundation by investing in and strengthening our teams that provide such critical care to our clients, expanding access for families, and ensuring that Acorn continues to grow in a way that reflects its values." Iyer holds a bachelor's degree in electronics and communication engineering from The University of Madras, a master's degree in electrical engineering, and an MBA from Duke University. Rich Hallworth, who has led Acorn Health since 2023, will retire from the CEO role and continue to serve as an active member of Acorn Health's board of directors. "It has been a privilege to lead Acorn Health and to work alongside such a talented team," Hallworth said. "As I transition into retirement, I am pleased to remain an active member of the board and continue supporting the organization's mission. I have full confidence in Mony's leadership and in the team's ability to carry Acorn forward." About Acorn Health: Acorn Health is accredited by the Autism Commission on Quality and offers both center-based and in-home services nationwide in more than 70 centers located throughout Florida, Illinois, Maryland, Michigan, Pennsylvania, Tennessee, and Virginia. Founded in 2018, Acorn is committed to providing industry-leading quality clinical care through applied behavioral analysis (ABA) therapy to give children diagnosed with autism spectrum disorder (ASD) the opportunity to live more independent and meaningful lives. Cases of ASD are on the rise; according to the Centers for Disease Control and Prevention, one in 31 children is living with ASD. ABA therapy, a program endorsed by the U.S. Surgeon General, provides individualized plans for each patient based on agreed upon clear, measurable goals with the child's family. Acorn Health uses its proprietary Behavioral Health Index to measure success in ways that are easily understood by families, clinicians and educators. To learn more about Acorn Health, visit and to learn about career opportunities, visit To inquire about ABA therapy at Acorn Health, please call 844.244.1818. Follow us at and View source version on Contacts Media contact: Lynne Blasi, 703.582.3973, lynne@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Johnson & Johnson Shares Rally as Pharma Giant Invests $2 Billion in U.S. Expansion
This article first appeared on GuruFocus. Aug 21 - Johnson & Johnson (NYSE:JNJ) shares moved up on Thursday morning after the healthcare giant committed $2 billion to expand its U.S. manufacturing base, a move designed to offset potential tariffs on imported drugs. Warning! GuruFocus has detected 3 Warning Sign with NDSN. Is JNJ fairly valued? Test your thesis with our free DCF calculator. The company said it will build a 160,000-square-foot facility at Fujifilm Biotechnologies' new Holly Springs, North Carolina site. The investment, spread over 10 years, aims to produce more advanced medicines domestically and create about 120 jobs. J&J added it plans to announce further facility expansions across the U.S. in the months ahead. The pledge comes as former President Donald Trump prepares to roll out pharmaceutical tariffs that could climb as high as 250%. In March, J&J outlined plans to increase its U.S. investments by 25% to more than $55 billion over four years. Other global drugmakers, including AstraZeneca (NASDAQ:AZN) and Eli Lilly (NYSE:LLY), have also boosted U.S. manufacturing spending this year to prepare for shifting trade policies. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Entrepreneur
2 hours ago
- Entrepreneur
Stop Losing Customers — 5 Friction Fixes That Boost Conversions
Small, targeted fixes in the customer journey — like building trust upfront, reducing friction and automating steps — can cut abandonment and boost conversion rates without a full redesign. Opinions expressed by Entrepreneur contributors are their own. At Bask Health, we once forced every new patient to download a separate app just to upload their ID. Only 40% of them made it through. Six weeks of development, thousands of dollars spent, and we called it a funnel. That one decision cost us more patients than any Facebook ad ever brought in. Turns out, healthcare has a cart abandonment problem, just like ecommerce. But instead of a forgotten pair of sneakers, it's unbooked visits, lost revenue and patients who still need help. And unlike a shopping cart, an abandoned patient is a real person who might go untreated. The irony? Most platforms are a few micro-fixes away from major conversion lifts. We're talking about small, scrappy interventions that boost visit completion rates, no full redesigns required. Fix the friction, finish more visits. Here's how we sealed the biggest leaks in our patient flow and increased completion by 15%. Related: 5 Simple Ways You Can Decrease Shopping-Cart Abandonment 1. Scare fewer patients at step one First-time users are already skeptical. They're worried about cost, privacy and whether this whole "online doctor thing" is legit. Add a dense form or legalese about data, and they're gone. What worked for us: Put a "HIPAA Secure" badge near the call to action badge near the call to action Include a one-line promise like: "We never sell or share your info." Use plain English, not compliance jargon Patients don't read your privacy policy. But they do feel your tone. So do the work for them. Space your elements clearly. Use icons sparingly. And write like a human. People aren't comparing you to other clinics. They're comparing you to Uber and Amazon. Tip: Follow HIPAA's privacy guidance for what you must, and can, say. Patients feel safer when they know what's happening. 2. Escalate to live chat before they bail We assumed patients would reach out if they had questions. They didn't. They just left. Page stalled, visit lost. Here's what helped: Auto-trigger live chat if users pause at critical fields (like insurance input or ID upload) Escalate from bot to human in under 15 seconds Train reps to reassure, not upsell Live chat isn't optional anymore. It's the new front desk. After implementing this flow, we saw a 12% increase in form completions, just from helping people in the moment when they were getting stuck. Make sure your chat tool integrates cleanly with your CRM. Set KPIs: sub-30-second response time, sub-3-minute resolution. If a patient wants care at midnight, don't make them wait for support until morning. 3. Cut steps like a chef, especially ID uploads Requiring patients to scan their ID in a specific browser? We may as well have asked for a fax. And the worst part? We didn't know it was broken until a user emailed us three days later. Quick wins: Accept image uploads from phone camera rolls Offer drag-and-drop + file upload options Use OCR tech to auto-fill name and DOB OCR's identity verification guidance is flexible enough; don't make it harder than it needs to be. Also: test this flow on iPhones, Androids, tablets and old browsers. Friction hides in tech gaps. The best checkout is one that disappears into the background. Related: 3 Fatal Ecommerce Mistakes You Must Not Make 4. Automate the boring stuff Nobody wants to type their insurance group number at 11 p.m. That's when they're finally booking care, and we're greeting them with paperwork. Here's what helped: Enable camera capture of insurance cards Use autofill for returning patients Pre-load common insurer names and plan types These changes cut our manual data cleanup by half and improved patient throughput without adding support headcount. Most importantly, they helped people finish the booking while they still had momentum. Automation isn't about removing humans. It's about clearing the path so your humans can focus on care, not copy-pasting from a broken webform. 5. Confirm with confidence Our first "success" screen said: Thank you. That's it. No confirmation number. No next steps. Patients didn't know if they were actually booked or if they just wasted 15 minutes. Fixes: Add a visible progress bar throughout the flow End with: "You're confirmed. Here's what happens next." Send immediate confirmation via email and SMS with visit details We also added a preview screen that lets patients review, cancel or reschedule their appointment in one click. Empowering the user reduces support tickets and gives them a sense of control. Remember: this is healthcare. An ambiguous checkout creates anxiety. A clear one builds trust. Close the leaks, book more patients We built these fixes after getting burned by our bad assumptions. We didn't need a brand strategist. We needed friction audits and brutal honesty. Healthcare abandonment isn't about laziness, it's about user experience. Your challenge: audit your patient flow this week. Pull the data. Watch users abandon in real time. Where are they dropping? What would it take to lift conversions by just 3%? (That's often six figures of revenue.) Here's your cheat sheet: Add visible trust cues upfront Make support accessible instantly Remove unnecessary steps Auto-fill every field you legally can Confirm like you mean it This isn't about being perfect. It's about being good enough to get them through the door. Remember: the patient doesn't care how clever your design is. They care that it works. Healthcare doesn't need more bells and whistles. It needs less friction. And fewer abandoned carts.
